NCT04606771 - A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2020

Primary Completion Date

December 21, 2022

Study Completion Date

March 30, 2026

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Osimertinib + Savolitinib

"Osimertinib 80 mg oral QD~Savolitinib 300mg oral QD"

DRUG

Savolitinib + Placebo

"Savolitinib 300mg Oral QD~Placebo to Osimertinib 80mg oral QD"

Trial Locations (21)

100

Research Site, Taipei

235

Research Site, Taipei

333

Research Site, Taoyuan

402

Research Site, Taichung

10210

Research Site, Bangkok

10300

Research Site, Bangkok

10330

Research Site, Bangkok

10400

Research Site, Bangkok

10700

Research Site, Bangkok

11217

Research Site, Taipei

40002

Research Site, Khon Kaen

50200

Research Site, Muang

90110

Research Site, Hat Yai

91010

Research Site, Duarte

95817

Research Site, Sacramento

100000

Research Site, Hanoi

Research Site, Hà Nội

110085

Research Site, Delhi

400053

Research Site, Mumbai

700000

Research Site, Ho Chi Minh City

C1120AAT

Research Site, Buenos Aires